{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:26:22Z","timestamp":1788456382589,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Bone-modifying agents (BMAs) reduce the incidence of skeletal-related events (SREs) and are thus recommended for breast cancer patients with bone metastases. However, the risk factors for SREs during BMA treatment are not well-understood. This study evaluated the number and timing of SREs from case studies to identify these factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>The medical records of 534 women with breast cancer who developed bone metastases between 1999 and 2011 were reviewed. SREs were defined as a pathologic fracture, spinal cord compression, or the need for bone irradiation or surgery. Multiple variables were assessed and were analyzed by using the Cox proportional hazard analyses and the Andersen and Gill method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Multivariate analyses for both the time to the first SRE and the primary and subsequent SRE frequency demonstrated that significant baseline risk factors included luminal B type disease, a history of palliative radiation therapy, BMA treatment within 2 years, and elevated serum calcium levels at the time of the initial BMA dose. Additionally, for the time to the first SRE and for the primary and subsequent SRE frequency, the presence of extraskeletal metastases and BMA administration initiation \u22656 months after the detection of bone metastases were also significant risk factors, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>In breast cancer patients with bone metastases, more vigilant observation should be considered for patients with the identified risk factors. To reduce the risk for SRE, BMAs should be administered within 6 months of bone metastases diagnosis and before palliative radiation therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0377","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T02:23:20Z","timestamp":1458008600000},"page":"508-513","source":"Crossref","is-referenced-by-count":30,"title":["Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents"],"prefix":"10.1093","volume":"21","author":[{"given":"Ryota","family":"Tanaka","sequence":"first","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"},{"name":"c Department of Dermatology, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"a Biostatistics and Bioinformatics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"a Biostatistics and Bioinformatics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"a Biostatistics and Bioinformatics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kodaira","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harukaze","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"a Biostatistics and Bioinformatics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Shimizu","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"c Department of Dermatology, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[{"name":"a Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"2021122309521728400_B1","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2021122309521728400_B2","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s10552-010-9604-8","article-title":"Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women","volume":"21","author":"Shin","year":"2010","journal-title":"Cancer Causes Control"},{"key":"2021122309521728400_B3","doi-asserted-by":"crossref","first-page":"g3608","DOI":"10.1136\/bmj.g3608","article-title":"An update on the medical management of breast cancer","volume":"348","author":"Yeo","year":"2014","journal-title":"BMJ"},{"key":"2021122309521728400_B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2021122309521728400_B5","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1200\/JCO.2007.14.1168","article-title":"Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer","volume":"26","author":"Dawood","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309521728400_B6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"suppl 4","key":"2021122309521728400_B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: Clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"The Oncologist"},{"key":"2021122309521728400_B8","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309521728400_B9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"2021122309521728400_B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122309521728400_B11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122309521728400_B12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"2021122309521728400_B13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122309521728400_B14","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 3","key":"2021122309521728400_B15","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2021122309521728400_B16","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.6004\/jnccn.2014.0214","article-title":"Improving the use of intravenous bisphosphonates in women with breast cancer metastatic to bone","volume":"12","author":"Mortimer","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122309521728400_B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2011.000212","article-title":"American Society of Clinical Oncology clinical practice guideline update: Recommendations on the role of bone-modifying agents in metastatic breast cancer","volume":"7","author":"Van Poznak","year":"2011","journal-title":"J Oncol Pract"},{"key":"2021122309521728400_B18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","article-title":"Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis","volume":"11","author":"Hatoum","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"2021122309521728400_B19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox regression-model for counting-processes - a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"2021122309521728400_B20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2407-5-89","article-title":"Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer","volume":"5","author":"Liauw","year":"2005","journal-title":"BMC Cancer"},{"key":"2021122309521728400_B21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-009-0645-z","article-title":"Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting","volume":"18","author":"Trinkaus","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122309521728400_B22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122309521728400_B23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122309521728400_B24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"Major","year":"2009","journal-title":"BMC Cancer"},{"key":"2021122309521728400_B25","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"key":"2021122309521728400_B26","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309521728400_B27","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122309521728400_B28","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/4\/508\/41874488\/oncolo_21_4_508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/4\/508\/41874488\/oncolo_21_4_508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:03:42Z","timestamp":1640318622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/4\/508\/6401327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,14]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0377","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4,1]]},"published":{"date-parts":[[2016,3,14]]}}}